Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

DEVELOPMENT OF NOVEL FURANOCOUMARIN DIMERS AS POTENT AND SELECTIVE INHIBITORS OF CYP3A4

E. Row, S. A. Brown, A. V. Stachulski and M. S. Lennard
Drug Metabolism and Disposition February 2006, 34 (2) 324-330; DOI: https://doi.org/10.1124/dmd.105.007294
E. Row
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. A. Brown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. V. Stachulski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. S. Lennard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Grapefruit juice has been found to cause an increase in the oral bioavailability of many therapeutic agents. Such interactions are believed to result from the mechanism-based inhibition of CYP3A4 activity in the intestine. Furanocoumarin dimers present in the juice have been found to be extremely potent inhibitors of CYP3A4 activity. The aim of this work was to synthesize and test a series of dimers with a view to defining the relationship between structure and inhibitory activity and establish whether they might make suitable probes of CYP3A4 activity. Eleven furanocoumarin dimers were synthesized and evaluated as inhibitors of CYP3A4 using human liver microsomes, with testosterone as the marker substrate. Four of the most potent dimers were also investigated for their effects on CYP3A4 activity in the human intestine and on five additional hepatic cytochrome P450 isoforms. The dimers showed potent dose-dependent inhibition of CYP3A4 activity in both liver and intestine; IC50 values ranged from 0.021 ± 0.002 to 0.146 ± 0.041 μM (mean ± S.D. n = 3). Of the four dimers evaluated further, all showed time-dependent inhibition of CYP3A4 activity. 88Prop showed moderate inhibition of both CYP2C19 and CYP1A2 with IC50 values of 4.42 ± 0.01 and 1.98 ± 0.34 μM, 88Octa was found to inhibit CYP2C19 (IC50 = 3.16 ± 0.01 μM) and 58Prop to inhibit CYP1A2 (IC50 = 2.39 ± 0.77 μM). Minimal inhibition of CYP2D6 and CYP2C9 was observed (IC50 > 10 μM). In conclusion, all the dimers tested were extremely potent inhibitors of CYP3A4 activity. In particular, dimer 55EE was highly selective toward the enzyme, suggesting that this compound is a suitable probe for determining the contribution of CYP3A4 to drug metabolism.

Footnotes

  • We thank the Biotechnology and Biological Sciences Research Council (BBSRC) for financial support.

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.105.007294.

  • ABBREVIATIONS: P450, cytochrome P450; EI, electron impact; CI, chemical ionization; TLC, thin-layer chromatography; DMF, dimethylformamide; DMSO, dimethyl sulfoxide; 88cBUT, 9,9′-[(2Z)-but-2-ene-1,4-diylbis(oxy)]bis(7H-furo[3,2-g]chromen-7-one; 88tBUT, 9,9′-[(2E)-but-2-ene-1,4-diylbis-(oxy)]bis(7H-furo[3,2-g]chromen-7-one; 88Prop, 9,9′-[propane-1,3-diylbis(oxy)]bis(7H-furo[3,2-g]chromen-7-one; 88Octa, 9,9′-[(octane-1,8-diylbis(oxy)]bis(7H-furo[3,2-g]chromen-7-one; 88EE, 9,9′-[(ethane-1,2-diylbis(oxyethane-2,1-diyloxy)]bis(7H-furo[3,2-g]chromen-7-one; 55cBut, 4,4′-[(2Z)-but-2-ene-1,4-diylbis(oxy)]bis(7H-furo[3,2-g]chromen-7-one; 55tBut, 4,4′-[(2E)-but-2-ene-1,4-diylbis(oxy)bis(7H-furo[3,2-g]chromen-7-one; 55Prop, 4,4′-[(propane 1,3-diylbis(oxy)]bis(7H-furo[3,2-g]chromen-7-one; 55Octa, 4,4′-[octane-1,8-diylbis(oxy)]bis(7H-furo[3,2-g]chromen-7-one; 55EE, 4,4′-[ethane-1,2-diylbis(oxyethane-1,2-diyloxy)]bis(7H-furo[3,2-g]chromen-7-one; 58Prop, 4-({3-[(7-oxo-7H-furo[3,2-g]chromen-9-yl)oxy]propoxy}-7H-furo[3,2-g]chromen-7-one; 58Octa, 4-({8-[(7-oxo-7H-furo[3,2-g]chromen-9-yl)oxy]octyl}oxy)-7H-furo[3,2-g]chromen-7-one.

  • ↵1 Current affiliations: Avecia Ltd., Huddersfield, West Yorkshire, U.K. (S.A.B.); and The University of Liverpool, Department of Chemistry, Robert Robinson Laboratories, Liverpool, U.K. (E.R., A.V.S.).

    • Received September 9, 2005.
    • Accepted November 15, 2005.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 34 (2)
Drug Metabolism and Disposition
Vol. 34, Issue 2
1 Feb 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
DEVELOPMENT OF NOVEL FURANOCOUMARIN DIMERS AS POTENT AND SELECTIVE INHIBITORS OF CYP3A4
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

DEVELOPMENT OF NOVEL FURANOCOUMARIN DIMERS AS POTENT AND SELECTIVE INHIBITORS OF CYP3A4

E. Row, S. A. Brown, A. V. Stachulski and M. S. Lennard
Drug Metabolism and Disposition February 1, 2006, 34 (2) 324-330; DOI: https://doi.org/10.1124/dmd.105.007294

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

DEVELOPMENT OF NOVEL FURANOCOUMARIN DIMERS AS POTENT AND SELECTIVE INHIBITORS OF CYP3A4

E. Row, S. A. Brown, A. V. Stachulski and M. S. Lennard
Drug Metabolism and Disposition February 1, 2006, 34 (2) 324-330; DOI: https://doi.org/10.1124/dmd.105.007294
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics